{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:12:56Z","timestamp":1788329576633,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Open Research Project of the Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education), Gannan Medical University"},{"name":"Scientific Research Foundation of State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory"},{"name":"Xiamen International Student Research Project and Shenzhen Science and Technology Program"},{"name":"Medical Innovation Project of Fujian Provincial Health Commission"},{"name":"Xiamen Natural Science Foundation Project"},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39540-1","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:46:15Z","timestamp":1771875975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Claudin18.2 promote gastric cancer proliferation by activating MCM2\/5"],"prefix":"10.1038","volume":"16","author":[{"given":"Bowen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanzhuoran","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyi","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingke","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"39540_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"39540_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki, A., Osumi, H., Yoshino, K. & Yamaguchi, K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer. 27, 907\u2013931 (2024).","journal-title":"Gastric Cancer"},{"key":"39540_CR3","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1038\/s41388-023-02835-y","volume":"42","author":"PM Kasi","year":"2023","unstructured":"Kasi, P. M. et al. Neoadjuvant Botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene 42, 3252\u20133259 (2023).","journal-title":"Oncogene"},{"key":"39540_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fon-2020-0737","volume":"17","author":"HC Chung","year":"2021","unstructured":"Chung, H. C. et al. First-line pembrolizumab\/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 17, 491\u2013501 (2021).","journal-title":"Future Oncol."},{"key":"39540_CR5","doi-asserted-by":"crossref","unstructured":"Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in Korean patients with HER2-Negative, Untreated, unresectable advanced or recurrent gastric or gastroesophageal junction cancer: subgroup analysis of a Randomized, Multicenter, Double-Blind phase 3 trial (ATTRACTION-4). Cancer Res. Treat (2025).","DOI":"10.4143\/crt.2024.913"},{"key":"39540_CR6","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","volume":"30","author":"X Gao","year":"2024","unstructured":"Gao, X. et al. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 compassion-04 trial. Nat. Med. 30, 1943\u20131951 (2024).","journal-title":"Nat. Med."},{"key":"39540_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jjco\/hyac188","volume":"53","author":"H Satake","year":"2023","unstructured":"Satake, H. et al. Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062. Jpn J. Clin. Oncol. 53, 221\u2013229 (2023).","journal-title":"Jpn J. Clin. Oncol."},{"key":"39540_CR8","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.2217\/fon-2021-0176","volume":"17","author":"J Tabernero","year":"2021","unstructured":"Tabernero, J. et al. KEYNOTE-859: a phase III study of pembrolizumab plus chemotherapy in gastric\/gastroesophageal junction adenocarcinoma. Future Oncol. 17, 2847\u20132855 (2021).","journal-title":"Future Oncol."},{"key":"39540_CR9","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. Jama 330, 2064\u20132074 (2023).","journal-title":"Jama"},{"key":"39540_CR10","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu, M. Z. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. Bmj 385, e078876 (2024).","journal-title":"Bmj"},{"key":"39540_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tibs.2018.09.008","volume":"44","author":"S Tsukita","year":"2019","unstructured":"Tsukita, S., Tanaka, H. & Tamura, A. The claudins: from tight junctions to biological systems. Trends Biochem. Sci. 44, 141\u2013152 (2019).","journal-title":"Trends Biochem. Sci."},{"key":"39540_CR12","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1007\/s11033-013-2724-y","volume":"40","author":"YJ Hu","year":"2013","unstructured":"Hu, Y. J., Wang, Y. D., Tan, F. Q. & Yang, W. X. Regulation of paracellular permeability: factors and mechanisms. Mol. Biol. Rep. 40, 6123\u20136142 (2013).","journal-title":"Mol. Biol. Rep."},{"key":"39540_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"\u00d6 T\u00fcreci","year":"2011","unstructured":"T\u00fcreci, \u00d6. et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 481, 83\u201392 (2011).","journal-title":"Gene"},{"key":"39540_CR14","doi-asserted-by":"publisher","first-page":"1132319","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Targeting CLDN18.2 in cancers of the Gastrointestinal tract: new drugs and new indications. Front. Oncol. 13, 1132319 (2023).","journal-title":"Front. Oncol."},{"key":"39540_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","volume":"155","author":"SJ Hagen","year":"2018","unstructured":"Hagen, S. J. et al. Loss of tight junction protein Claudin 18 promotes progressive neoplasia development in mouse stomach. Gastroenterology 155, 1852\u20131867 (2018).","journal-title":"Gastroenterology"},{"key":"39540_CR16","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin, U. et al. Claudin-18 splice variant 2 is a Pan-Cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624\u20137634 (2008).","journal-title":"Clin. Cancer Res."},{"key":"39540_CR17","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi, T. et al. claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol. Cell. Biol. 21, 7380\u20137390 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"39540_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille, S., Xu, J. & Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell. Biol. 15, 178\u2013196 (2014).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"39540_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1369\/0022155411420569","volume":"59","author":"M Tanaka","year":"2011","unstructured":"Tanaka, M. et al. Claudin-18 is an Early-Stage marker of pancreatic carcinogenesis. J. Histochem. Cytochem. 59, 942\u2013952 (2011).","journal-title":"J. Histochem. Cytochem."},{"key":"39540_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/PAS.0b013e31815701f3","volume":"32","author":"ZE Karanjawala","year":"2008","unstructured":"Karanjawala, Z. E. et al. New markers of pancreatic cancer identified through differential gene expression analyses: Claudin 18 and Annexin A8. Am. J. Surg. Pathol. 32, 188\u2013196 (2008).","journal-title":"Am. J. Surg. Pathol."},{"key":"39540_CR21","doi-asserted-by":"crossref","unstructured":"T\u00fcreci, \u00d6., Mitnacht-Kraus, R., W\u00f6ll, S., Yamada, T. & Sahin, U. Characterization of Zolbetuximab in pancreatic cancer models. Oncoimmunology ; 8. (2019).","DOI":"10.1080\/2162402X.2018.1523096"},{"key":"39540_CR22","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"39540_CR23","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"39540_CR24","doi-asserted-by":"crossref","unstructured":"Peker, P. et al. Systemic Immune-Inflammation index as a prognostic marker in gastric and gastroesophageal junction cancers receiving perioperative FLOT therapy. Medicina-Lithuania ; 61. (2025).","DOI":"10.3390\/medicina61091614"},{"key":"39540_CR25","doi-asserted-by":"publisher","first-page":"1143154","DOI":"10.3389\/fonc.2023.1143154","volume":"13","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Single and combined use of the platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and systemic immune-inflammation index in gastric cancer diagnosis. Front. Oncol. 13, 1143154 (2023).","journal-title":"Front. Oncol."},{"key":"39540_CR26","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res."},{"key":"39540_CR27","doi-asserted-by":"publisher","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A Lanczky","year":"2021","unstructured":"Lanczky, A. & Gyorffy, B. Web-Based survival analysis tool tailored for medical research (KMplot): development and implementation. J. Med. Internet Res. 23, e27633 (2021).","journal-title":"J. Med. Internet Res."},{"key":"39540_CR28","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1093\/bioinformatics\/bty411","volume":"34","author":"CJ Liu","year":"2018","unstructured":"Liu, C. J. et al. GSCALite: a web server for gene set cancer analysis. Bioinformatics 34, 3771\u20133772 (2018).","journal-title":"Bioinformatics"},{"key":"39540_CR29","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457\u2013462 (2016).","journal-title":"Nucleic Acids Res."},{"key":"39540_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nsmb.3374","volume":"24","author":"YL Zhai","year":"2017","unstructured":"Zhai, Y. L. et al. Open-ringed structure of the Cdt1-Mcm2-7 complex as a precursor of the MCM double hexamer. Nat. Struct. Mol. Biol. 24, 300\u2013 (2017).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"39540_CR31","doi-asserted-by":"publisher","first-page":"643872","DOI":"10.3389\/fonc.2021.643872","volume":"11","author":"BS Ungureanu","year":"2021","unstructured":"Ungureanu, B. S. et al. Clinicopathologic relevance of Claudin 18.2 expression in gastric cancer: A Meta-Analysis. Front. Oncol. 11, 643872 (2021).","journal-title":"Front. Oncol."},{"key":"39540_CR32","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde, C. et al. Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J. Clin. Oncol. 49, 870\u2013876 (2019).","journal-title":"Jpn J. Clin. Oncol."},{"key":"39540_CR33","doi-asserted-by":"crossref","unstructured":"Clements, M. E., Willis, S. E. III, Ortiz, M. K., Zalesak-Kravec, L. & Lombard, S. C et al. CLDN18\/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma; 42: 4089\u20134089. (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.4089"},{"key":"39540_CR34","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","volume":"475","author":"M Dottermusch","year":"2019","unstructured":"Dottermusch, M., Kr\u00fcger, S., Behrens, H. M., Halske, C. & R\u00f6cken, C. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study. Virchows Arch. 475, 563\u2013571 (2019).","journal-title":"Virchows Arch."},{"key":"39540_CR35","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","volume":"22","author":"A Arnold","year":"2020","unstructured":"Arnold, A. et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin. Transl Oncol. 22, 2357\u20132363 (2020).","journal-title":"Clin. Transl Oncol."},{"key":"39540_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","volume":"121","author":"I Coati","year":"2019","unstructured":"Coati, I. et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Brit J. Cancer. 121, 257\u2013263 (2019).","journal-title":"Brit J. Cancer"},{"key":"39540_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1922","volume":"208","author":"Y Sanada","year":"2006","unstructured":"Sanada, Y. et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J. Pathol. 208, 633\u2013642 (2006).","journal-title":"J. Pathol."},{"key":"39540_CR38","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.21037\/jgo-20-463","volume":"11","author":"YF Lu","year":"2020","unstructured":"Lu, Y. F. et al. Correlation between Claudin-18 expression and clinicopathological features and prognosis in patients with gastric cancer. J. Gastrointest. Oncol. 11, 1253\u20131260 (2020).","journal-title":"J. Gastrointest. Oncol."},{"key":"39540_CR39","doi-asserted-by":"publisher","first-page":"e74757","DOI":"10.1371\/journal.pone.0074757","volume":"8","author":"T Oshima","year":"2013","unstructured":"Oshima, T. et al. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. Plos One. 8, e74757 (2013).","journal-title":"Plos One"},{"key":"39540_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","volume":"12","author":"KH Jun","year":"2014","unstructured":"Jun, K. H., Kim, J. H., Jung, J. H., Choi, H. J. & Chin, H. M. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int. J. Surg. 12, 156\u2013162 (2014).","journal-title":"Int. J. Surg."},{"key":"39540_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5230\/jgc.2020.20.e33","volume":"20","author":"SR Kim","year":"2020","unstructured":"Kim, S. R. et al. Clinical significance of CLDN18.2 expression in metastatic Diffuse-Type gastric cancer. J. Gastric Cancer. 20, 408\u2013420 (2020).","journal-title":"J. Gastric Cancer"},{"key":"39540_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia, K. et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 20, 223 (2022).","journal-title":"BMC Med."},{"key":"39540_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","volume":"23","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer. BMC Gastroenterol. 23, 283 (2023).","journal-title":"BMC Gastroenterol."},{"key":"39540_CR44","first-page":"G336","volume":"294","author":"K Yano","year":"2008","unstructured":"Yano, K., Imaeda, T. & Niimi, T. Transcriptional activation of the human gene promoter through two AP-1 motifs in PMA-stimulated MKN45 gastric cancer cells. Am. J. Physiol-Gastr L. 294, G336\u2013G343 (2008).","journal-title":"Am. J. Physiol-Gastr L"},{"key":"39540_CR45","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/jcb.23095","volume":"112","author":"T Ito","year":"2011","unstructured":"Ito, T. et al. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. J. Cell. Biochem. 112, 1761\u20131772 (2011).","journal-title":"J. Cell. Biochem."},{"key":"39540_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","volume":"403","author":"K Takasawa","year":"2017","unstructured":"Takasawa, K. et al. Claudin-18 coupled with EGFR\/ERK signaling contributes to the malignant potentials of bile duct cancer. Cancer Lett. 403, 66\u201373 (2017).","journal-title":"Cancer Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39540-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:01:52Z","timestamp":1774609312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39540-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39540"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39540-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10263"}}